NVNha Voduc

Nha Voduc

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nha Voduc has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pilot study evaluating frailty-focused care for hospitalised patients with chronic obstructive pulmonary disease

    by Sunita Mulpuru, Melanie Chin, Delvina Hasimja, Jacqueline Sandoz, Nha Voduc, Smita Pakhale, Jiro Inoue, Joanne Cassidy, Caroline Tessier, Barbara D’eNtremont, et al.

    Background: Frailty is associated with morbidity and mortality among people with chronic obstructive pulmonary disease (COPD), yet there are no established care pathways to manage frail patients with COPD. To address this gap, we developed, implemented and assessed the feasibility of a new frailty-focused care model for patients hospitalised with exacerbations of COPD. Methods: We conducted a prospective cohort study among hospitalised patients with acute exacerbations of COPD in an academic hospital in Canada over 18 months. We developed and implemented a frailty-focused care model using the degree of frailty to guide personalised assessments, education, and care interventions during and after hospital discharge. We assessed the feasibility of using frailty-focused care in a real-world setting with prespecified targets for recruitment rate, care model completion and collection of patient-reported outcomes including symptom burden, health confidence, health status and self-management scores. Patients were followed up at 3 months after hospitalisation to reassess patient-reported outcomes. Results: 87 patients used the frailty-focused care model during hospitalisation, 58 consented to participate in this study and 45 (78%) completed 3-month postdischarge follow-up. 47% (n=21) were at least mildly frail at baseline, with 35% (n=20) at risk of frailty. Target recruitment of 50 patients was achieved, and all participants completed core elements of frailty-focused care, including frailty assessment, personalised education and discharge planning. Patient-reported outcomes were measured in all participants in hospital, and in 78% (n=45) patients at 3-month follow-up. 23% (n=13) of patients initially reported feeling confident to manage their health condition. This improved to 62% (n=28) at 3-month follow-up. Conclusions: This study provides a foundation to build innovative care models for frail individuals with COPD and shows it is feasible to use frailty-focused care in a real-world hospital setting. Future work requires strong patient engagement to better align frailty-focused care with patient-centred goals.


  • Open Access

    Operationalizing care in a hospital-based respirology clinic during a global pandemic

    by Christopher J. L. Stone, Sunita Mulpuru, Nha Voduc, Melanie Chin

    The novel coronavirus (SARS-CoV-2) pandemic has forced clinicians across Canada to abruptly adapt to a new reality of reduced contact with patients in ambulatory care settings. With minimal lead time, ambulatory clinics in Canada were required to adopt aggressive infection prevention and control measures while facing shortages of personal protective equipment and to enact strategies to urgently reorganize patient care. These adaptations included the conversion of ambulatory clinics to telephone or virtual care platforms. In 2015, the Public Health Agency of Canada (PHAC) published pandemic influenza preparedness guidelines highlighting the importance of pandemic preparedness planning in primary and ambulatory care settings, including clinic continuity planning and provisions for non in-person care. Despite these recommendations, hospital-based ambulatory clinics lacked formal strategic plans to adapt patient care processes during the SARS-CoV-2 outbreak. Thus, in a short time frame, clinics individually adapted their own patient care processes. This creates the potential for gaps in quality of medical care for patients across Canada. In this report, we describe the evolution and operationalization of care planning in our hospital-based respirology clinic, highlight the challenges faced, and make recommendations for respirology clinic adaptations based on available guidance. This process may be used as a foundation to guide future policy, discussion and guidelines for hospital-based respiratory care to ensure optimal preparedness during the next inevitable respiratory viral pandemic or possible worsening of the current pandemic.

  • Effect of benralizumab on asthma exacerbation rates in patients with severe asthma: Systematic review and meta-analysis

    by Masoud Mahdavian, Sarah A. Mallay, Shabnam Asghari, Nha Voduc, Jordan C. Pike

    BACKGROUND: Severe asthma patients require high-dose inhaled corticosteroids (ICS) plus a second controller medication to control their disease or remain inadequately controlled despite this. Benralizumab is a humanized, monoclonal antibody that targets the interleukin-5 receptor alpha-chain causing depletion of eosinophils. The aim of this meta-analysis was to determine whether Benralizumab reduces annual asthma exacerbation rates in patients with severe asthma. METHODS: A comprehensive search of electronic databases was performed to include published articles databases until June 16, 2017. Inclusion criteria were randomized, double-blind, placebo-controlled, phase 3 clinical trials that measured annual asthma exacerbation rates, and used Benralizumab as add-on treatment for severe asthmatic patients. The primary outcome was reduction in annual exacerbation rates. Outcomes were reported as rate ratios versus placebo. FINDINGS: From 1211 reviews articles, three articles with a combined 2730 patients were included in the meta-analysis. There was a significant reduction in annual exacerbation rates (rate ratio vs. placebo = 0.62, 95% CI 0.49 to 0.78, p < 0·0001), which is more pronounced in patients with elevated blood Eosinophil (rate ratio vs. placebo = 0.54, 95% CI 0.45 to 0.66, p < 0·00001). INTERPRETATION: Benralizumab significantly reduces annual exacerbation rates in severe asthma patients as an add-on treatment with minimal adverse events.


  • Open Access

    Middle Lobe Syndrome Due to Calcified Adenopathy

    by Akram Arab, Nha Voduc, Terence Moyana, Sunita Mulpuru


  • Open Access

    Pulmonary Actinomycosis in a Male Patient with a Tracheal Bronchus

    by Cecilia T Costiniuk, Nha Voduc, Carolina de Souza

    BACKGROUND: Tracheal bronchus is a congenital malformation comprising an abnormal bronchus originating from the trachea or other bronchus. This malformation has been associated with recurrent pneumonia in children, but is rarely associated with infection in adults.Actinomycesspecies are rare causes of necrotizing pneumonias that often masquerade as malignancy, lung abscesses and tuberculosis.METHODS AND RESULTS: A case involving a 46-year-old man with a tracheal bronchus and chronic pneumonia syndrome is presented. Bronchialveolar lavage and transthoracic needle biopsy demonstrated the presence ofActinomyces meyeriandFusobacteriumspecies.CONCLUSIONS: The present article reports the first documented case of actinomycosis occurring in a patient with a tracheal bronchus.